MRK
May 24, 2022 | Daily JAM, DIS, Dividend Income, DUK, Jubak Picks, KO, MRK, PEP, PFE, Top 50 Stocks, XLU |
Of course, there’s nothing even vaguely normal about a day when a stock falls 43% and takes much of the market with it.Snap’s (SNAP) plunge did take some surprising candidates along for the ride. Tesla (TSLA) dropped 6.93% on yet more bad news on production in its Shanghai factory. Disney (DIS) fell 4.01% just because. SentinelOne (S) was lower by 8.11% since everyone knows that cybersecurity stocks are just a fad.
But on balance, on the green side (and yes, there was a green side to the market) the market did what markets are supposed to do in the face of bad news and an increase in fear.
May 14, 2022 | ABBV, BMY, Daily JAM, MRK, PFE |
I can’t find Big Pharma stock in the green during Friday’s big rally. Which makes me question the staying power of Friday’s move. If the day’s gains were the result of a market bottom, wouldn’t everything be up? Even the very defensive drug stocks? Not as much as the tech losers of 2022 but still if the market had bottomed I’d expect these stocks to be in the green too. More evidence, I think, for my thesis that Friday was the result of technical trading in an over-sold market.
November 15, 2021 | Daily JAM, MRK, PFE, Videos |
I’m starting up my videos on JubakAM.com again–this time using YouTube as a platform. My sixty-ninth YouTube video “Trend of the Week Big Pharma for Safety” went up today.
October 3, 2021 | Daily JAM, MRK |
Stocks zoomed on Friday on news that Merck (MRK) had developed and successfully trialed a pill that ... To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing...
November 19, 2019 | Daily JAM, MRK |
Merck (MRK) has announced that it will raise its quarterly dividend by 11% to 61 cents a share in the first quarter of 2020. The dividend will be paid on January 8, 2020 to shareholders of record on December 16, 2019. When I revised my Dividend Portfolio holdings last...
November 12, 2019 | CMI, CMWAY, Daily JAM, DLR, IEF, ITW, KMI, MRK, MSFT, OKE, PAC, PFXF, Special Reports, VZ, WBK |
Just to put all the changes in my Dividend Portfolio in one list after my Special Report 3 Ways to Higher Income in a Low Yield Desert Here are the sells: Bank of America (BAC) as of November 1 ING Group (ING) as of November 1 Tapestry (TPR) as of November 1 Westpac...
July 5, 2019 | Daily JAM, MRK, PFE |
It's good to know that in this sometimes confusing and volatile market some things remain constant. A high-profile figure says something about the need to lower drug prices and drug stocks tumble. Whether the "something" is likely to result in action or not. Today it...
April 1, 2019 | Daily JAM, MRK, Stock Alerts |
Merck's cancer drug Keytruda continues to build global momentum. Today Merck (MRK) announced that China has approved Keytruda for first-line treatment of metastatic nonsquamous non-small cell lung cancer in combination with chemotherapy. The stock, which is a member...
February 26, 2019 | Daily JAM, Morning Briefing, MRK, PFE |
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry's business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today's hearing...
May 14, 2018 | Daily JAM, MRK |
President Donald Trump speech last week on drug prices, what he billed as “the most sweeping action in history to lower the price of prescription drugs for the American people,” didn’t deliver any of the ghosts and goblins that drug makers feared. Drug stocks by and large climbed on the proposals. Which turns stocks in the drug sector into one of the most interesting places to stash money for the next six months for investors looking for decent upside and above average safety.
May 1, 2018 | Daily JAM, MRK, Stock Alerts |
This morning before the New York markets opened Merck (MRK) reported earnings of $1.05 a share, ahead of the $1.00 a share forecast by Wall Street analysts. Earnings were up 19.3% from the first quarter of 2017. Revenue grew 6% to $10 billion. That narrowly missed the...
April 27, 2018 | Daily JAM, MRK, Stock Alerts |
News out of the imuno-oncology sector of the biotech world has hit stocks in my portfolios such as Incyte (INCY) and Nektar Therapeutics (NKTR) hard. But, I'd argue that it has left Keytruda and its owner Merck (MRK) in a measurably stronger position in the market for...
